Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
Phase 3
Completed
- Conditions
- Neoplasms, Unknown Primary
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 198
- Registration Number
- NCT00193596
- Locations
- 🇺🇸
Tower Oncology, Beverly Hills, California, United States
🇺🇸Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸Jackson Oncology Associates, Jackson, Mississippi, United States
Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer
Phase 1
Completed
- Conditions
- Esophagus Cancer
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 59
- Registration Number
- NCT00193128
- Locations
- 🇺🇸
Atlanta Cancer Care, Atlanta, Georgia, United States
🇺🇸Northeast Georgia Medical Center, Gainesville, Georgia, United States
🇺🇸Integrated Community Oncology Network, Jacksonville, Florida, United States
Preoperative or Postoperative Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 250
- Registration Number
- NCT00193310
Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00193336
Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma
Phase 2
Completed
- Conditions
- Multiple Myeloma
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2009-01-23
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193544
Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2016-05-27
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 37
- Registration Number
- NCT00193180
- Locations
- 🇺🇸
Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States
🇺🇸Methodist Cancer Center, Omaha, Nebraska, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 110
- Registration Number
- NCT00193050
© Copyright 2025. All Rights Reserved by MedPath